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Abstract Longevity and healthy aging are among the
most complex phenotypes studied to date. The heritability
of age at death in adulthood is approximately 25 %. Studies
of exceptionally long-lived individuals show that herita-
bility is greatest at the oldest ages. Linkage studies of
exceptionally long-lived families now support a longevity
locus on chromosome 3; other putative longevity loci differ
between studies. Candidate gene studies have identified
variants at APOE and FOXO3A associated with longevity;
other genes show inconsistent results. Genome-wide asso-
ciation scans (GWAS) of centenarians vs. younger controls
reveal only APOE as achieving genome-wide significance
(GWS); however, analyses of combinations of SNPs or
genes represented among associations that do not reach
GWS have identified pathways and signatures that con-
verge upon genes and biological processes related to aging.
The impact of these SNPs, which may exert joint effects,
may be obscured by gene-environment interactions or
inter-ethnic differences. GWAS and whole genome
sequencing data both show that the risk alleles defined by
GWAS of common complex diseases are, perhaps sur-
prisingly, found in long-lived individuals, who may toler-
ate them by means of protective genetic factors. Such
protective factors may ‘buffer’ the effects of specific risk
alleles. Rare alleles are also likely to contribute to healthy
aging and longevity. Epigenetics is quickly emerging as a
critical aspect of aging and longevity. Centenarians delay
age-related methylation changes, and they can pass this
methylation preservation ability on to their offspring. Non-
genetic factors, particularly lifestyle, clearly affect the
development of age-related diseases and affect health and
lifespan in the general population. To fully understand the
desirable phenotypes of healthy aging and longevity, it will
be necessary to examine whole genome data from large
numbers of healthy long-lived individuals to look simul-
taneously at both common and rare alleles, with impecca-
ble control for population stratification and consideration
of non-genetic factors such as environment.
Background
The basis of human longevity and healthy aging, and how
to achieve these desirable phenotypes, remain among the
principal challenges of biology and medicine. While an
understanding of lifestyle and environmental factors will
maximize our ability to prevent disease and maximize
health in the general population, studying the genetic basis
of longevity and healthy aging in exceptional individuals is
providing important biological insights. In model organ-
isms it has been possible to demonstrate effects of muta-
tions in genes that can extend lifespan nearly tenfold
(Ayyadevara et al. 2008). Studies of inbred lab strains and
of natural genetic variants in model organisms including
yeast and worms (Tissenbaum and Guarente 2002), flies
(Paaby and Schmidt 2009) and mice (Yuan et al. 2011)
have clearly implicated many specific genes in the lifespan
of these organisms. Our understanding of human lifespan
stands in contrast to this, with only one consistently rep-
licable genetic association, APOE, observed to date in
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several genome-wide association scans (GWAS) of lon-
gevity-related traits. This may be because healthy aging
and longevity are particularly complex traits, involving not
only maintenance of long-term function but also absence or
reduction of disease and other morbidities. It has been
proposed that human lifespan is influenced not only by
longevity assurance mechanisms and disease susceptibility
loci but also by the environment, gene–environment
interactions, and chance (Cournil and Kirkwood 2001). It
will be important to understand the effects of environment
(lifestyle) and of genetics, as well as how they interact to
affect health and lifespan.
The importance of age and aging is underscored by the
recognition that all common complex diseases increase
with age. Questions remain about whether aging is the
cause or effect of such diseases (Hekimi 2006). The study
of desirable phenotypes like longevity and healthy aging
has been referred to as ‘positive biology’ (Farrelly 2012).
Its premise is that understanding the basis for such desir-
able traits may allow us to design interventions to improve
human health.
This review was intended to summarize our current
understanding of genetic factors affecting the phenotypes of
longevity and healthy aging in humans, including the defi-
nition and heritability of these traits, and linkage, associa-
tion, and sequencing studies. The surprising and novel
findings that centenarians do not appear to have a relative
lack of common complex disease risk alleles, and that some
genetic variants appear to ‘buffer’ or protect against specific
risk alleles, are discussed in detail. Shorter summaries of the
findings related to somatic mosaicism and the promising
study of epigenetics of aging are included for completeness.
Aging, healthy aging, and longevity
The phenotypes used in studies of the genetics of human
aging are usually lifespan (age at death), longevity (long
life, usually defined as being a specific advanced age or
older at the time of study), exceptional longevity (defined
as attaining or exceeding a specific exceptional age), or
healthy aging (a combination of old age and health, often
defined as freedom from specific disorders or desirable
performance levels on functional tests). Longevity studies
focus on long-lived individuals (LLI), often centenarians
aged 100 or more years. One advantage of such studies is
the simplicity of phenotype definition. Healthy aging can
be defined in various ways, usually with regard to reaching
an at least moderately old age in the absence of certain
diseases or disabilities, and/or in the presence of desirable
traits such as intact cognition or mobility. Both types of
studies should be differentiated from the study of the
fundamental biological processes of aging (for example,
cellular senescence).
A major difference between longevity and healthy aging
studies is that the former focuses on lifespan, whereas the
latter is focused on healthspan. Lifespan and healthspan are
intimately related, however, and individuals who live
exceptionally long also tend to be healthy for much of their
lives. A landmark study of the health of supercentenarians
(aged 110–119), semisupercentenarians (aged 105–109),
centenarians (in this context aged 100–104), nonagenari-
ans, and younger controls found that the older the age
group, the greater the delay in onset of major disease
(Andersen et al. 2012). Remarkably, for every category of
increasing age, the hazard ratio for each of six disorders
(cancer, cardiovascular disease (CVD), dementia, hyper-
tension, osteoporosis, and stroke) was \1.0 relative to the
next oldest group. This delay in disease development and
postponement of cognitive and physical decline in the
oldest group amounted to a compression of morbidity
(Fries 1980). Based on these findings, Andersen et al.
(2012) suggest that a realistic and practical limit of human
lifespan is 110–115 years, close to that of the oldest doc-
umented person in the world to date, who lived to 122
(Robine and Allard 1998).
Women have a lower mortality rate than men at every
age, and women live longer than men in most human
populations. Any given exceptional age, therefore, is more
exceptional for men than for women. As noted by Sebas-
tiani and Perls (2012) 1 % of US women (but only 0.1 % of
men) born circa the turn of the last century lived to be 100.
Potential explanations for this difference include hormonal
and immune differences, hemizygosity of the X-chromo-
some in men (which may allow manifestation of unfavor-
able sex-linked variants), and unrecognized confounders
[reviewed in Newman and Murabito (2013)].
The heritability of lifespan and related traits
Age at death in adulthood has a heritability of approxi-
mately 25 % (summarized in Murabito et al. 2012). A
population-based study of 2,872 Danish twin pairs born
between 1870 and 1900 found that the heritability of adult
lifespan was 0.26 in men and 0.23 in women (Herskind
et al. 1996). This cohort was not only population-based but
nearly non-censored and, with follow-up for 94 years,
encompassed essentially the entire human lifespan.
Importantly, the heritability of longevity increases with
greater age. The heritability of living to at least 100 has
been estimated at 0.33 in women and 0.48 in men
(Sebastiani and Perls 2012). Male and female siblings of
US centenarians were 17-fold and eightfold more likely
(compared with US Social Security data) to reach the age
of 100, respectively (Perls et al. 2002). The increase in
heritability of longevity at greater age is consistent between
several studies. In over 20,000 Scandanavian twins,
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heritability of longevity was negligible from age 6–60, but
increased with age thereafter (Hjelmborg et al. 2006). Long
life was heritable in Icelanders aged over 70 years
(Gudmundsson et al. 2000). The siblings of Okinawan
centenarians show increased adult survival probability that
starts at age 55 and increases with age (Willcox et al.
2006); the authors speculate based in part on absence of
many age-related diseases from Okinawan (Bernstein et al.
2004) and other centenarians (Evert et al. 2003), that these
individuals have genetic factors that confer resistance to
such diseases and increase the likelihood of reaching
exceptional old age. The estimation of heritability also
depends on how it is studied; Murabito et al. (2012) note
that the Framingham heart study cohorts give much greater
estimates of heritability when longevity is studied as a
dichotomous trait (36 % heritability for survival to 65 and
40 % for survival to 85), compared with 16 % heritability
when age at death is treated as a continuous trait.
Clustering of longevity and healthy aging is observed in
families. Parents of centenarians born in approximately
1870 were sevenfold more likely than their contemporaries
to have lived to age 90–99; offspring of centenarian parents
showed lower prevalence of age-related disease than age-
matched control groups (Atzmon et al. 2004). Exceptional
familial clusters of extreme longevity have also been
reported (Perls et al. 2000). Healthy aging is also heritable.
Reed and Dick (2003) defined ‘wellness’ in male twins as
achieving the age of 70 free of heart attack, coronary
surgery, stroke, diabetes or prostate cancer, and showed
that this trait had a heritability exceeding 50 %.
Environment and lifestyle likely constitute much of the
remaining influence on human lifespan and healthspan.
These factors have varied greatly over time and may not
reflect the extrinsic factors that will affect the lifespan of
babies born today. Many members of the elderly and
centenarian cohorts under study today lived through times
of caloric restriction (e.g., the Great Depression) and grew
up before the use of antibiotics and vaccines became
commonplace. The selective pressures that influenced their
mortality are not identical to those experienced by later
generations, and this is an important consideration for
study design.
The importance of study design
Phenotype definition is particularly important in genetic
studies; it affects the interpretation and meaning of results,
and the ability to compare to the results of other studies.
Studies of longevity can include extreme longevity
(defined as living beyond a specific extreme age) or age at
death. Studies of healthy aging may use age to disease
onset, successful aging or wellness (which can also have a
variety of definitions), or other phenotypes (Manolio 2007).
Linkage or family-based association study designs, longi-
tudinal cohort studies, or case/control designs have been
used. Family-based designs have the advantage of being
robust to population stratification. Longitudinal cohorts
have the advantage of limiting sampling bias, but take time
and due to practical limits of size may not contain many
individuals of extreme age. Sample size is a consideration
for all these study designs. To date, the largest studies of
LLI are in the low thousands of subjects; this is much
smaller than the largest studies of common complex dis-
eases (which now include over 100,000 subjects), despite
the likely similar modest size of many of the genetic fac-
tors being sought.
Choice of a comparison group to contrast with excep-
tionally long-lived or exceptionally healthy elderly indi-
viduals is also critical. Health data for LLI can be
compared with archived data for deceased individuals of
the same birth cohort, but DNA samples from an ideal
comparison group (such as their birth cohort) are not
available. Case/control molecular genetic studies of long-
lived or healthy aged individuals often compare elderly
cases to younger controls. Potential pitfalls of such studies
include inadequate detection and control for population
stratification, particularly for populations that have expe-
rienced immigration of different ethnicities over time
(Nebel and Schreiber 2005). The use of principal compo-
nents analysis (Price et al. 2006) or genomic controls
(Devlin and Roeder 1999) can mitigate this problem, as can
the conduct of studies within specific ethnic groups (Bar-
zilai et al. 2001). In the case/control design, the control
group is also expected to contain individuals who will go
on to become equivalent to cases; their presence in the
control group reduces power. Environmental factors must
be acknowledged in such studies as potential confounders;
inevitably, the cases and controls have lived in different
times and experienced different lifestyles. A way to miti-
gate some of these problems; however, is to choose con-
trols that are no older than 50 (Halaschek-Wiener et al.
2008) because in modern day developed countries, mor-
tality before age 50 is minimal. Choosing a comparison
group\50 years of age makes the control group essentially
an ‘unselected’ group with regard to mortality from age-
related diseases. Choosing a control group in their 70 or 80,
however, would exacerbate this issue, as the control group
would fail to include individuals who died in their 50’s or
60’s.
Several studies, such as the Longevity Gene Study
(Barzilai et al. 2001), the Leiden Longevity Study (LLS)
(Mooijaart et al. 2011), the New England Centenarian
Study (NECS) (Terry et al. 2004), and the Long Life
Family Study (LLFS) (Newman et al. 2011) include com-
parisons of the offspring of LLI (who are assumed to have
inherited some longevity factors) to contemporary age-
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matched controls. They have observed that the offspring of
LLI have more favorable blood lipid profiles (Barzilai et al.
2001; Newman et al. 2011) and lower prevalence of
hypertension and metabolic and cardiovascular disease
(Atzmon et al. 2004; Westendorp et al. 2009; Newman
et al. 2011) and all-cause mortality (Terry et al. 2004) than
age-matched controls. Comparison of the offspring of LLI
with their contemporaries controls for cohort effects such
as variation in BMI in human populations over time; it has
the limitation, however, of under-estimating the difference
in phenotypes and genotypes that would presumably be
observed if the LLI could be compared with their largely
long-deceased birth cohort.
Linkage studies of longevity and healthy aging
Linkage studies of long-lived sibships or extended pedi-
grees with exceptionally long-lived individuals have iden-
tified several putative and one replicated longevity linkage.
In 2001, the NECS (Puca et al. 2001) reported a 10-cM sib-
pair based linkage scan of 308 individuals in 137 sibships
with exceptional longevity (defined as having a proband of
at least 98 and a 91-year-old male or 95-year-old female
sib). They found significant evidence for linkage of lon-
gevity to a region around D4S1564. Suggestive support for
this region was obtained through analysis of 95 concordant
pairs of fraternal male twins with a wellness phenotype
(age at least 70 with no overt CVD or prostate cancer)
(Reed et al. 2004). Initial convergence of two linkage
studies with very different phenotypes led to excitement
about this region and its suspected role in longevity and
health. Subsequent study of the region focused in part on a
regional biological candidate gene, microsomal triglyceride
transfer protein (MTP), identified through haplotype anal-
ysis (Geesaman et al. 2003).
In 2010 a larger and higher density linkage study
(Boyden and Kunkel 2010) expanded on the initial NECS
resource, with a genome-wide linkage study of 279 fami-
lies with multiple long-lived sibs 90 years and older,
including 129/137 of those previously described (Puca
et al. 2001). A limitation of this study was the use of
expected life span (estimated from age- and gender-specific
life expectancies) for the 70 % of subjects who were still
living. This analysis of 9,751 SNPs found just-significant
LOD scores at 3p22-24 and 9q31-34, as well as modest
evidence for linkage at the original site, 4q22-25 and
possibly at 12q. A larger study (Kerber et al. 2012) repli-
cated the linkage of 3p22-24 to extreme longevity and
identified possible additional loci. Working with 732 sub-
jects from the Utah population database and database and
population controls, including 433 Caucasian individuals
aged 86–109 who showed a phenotype including both
excess individual longevity (the difference between
observed and expected lifespan) and excess familial lon-
gevity (a weighted average of excess longevity for all
family members), they used a linkage screen with 1,100
microsatellite markers to identify a strongly suggestive
peak at 3p at the same position as Boyden and Kunkel.
Meta-analysis of linkage in the Utah and New England data
sets supported linkage at the chromosome 3 locus. Other
linkage peaks were observed in the Utah data at 18q23-24,
8q23, and 17q21; meta-analysis provided additional sup-
port but not outright replication for 8q, 9q, and 17q. The
new data; however, did not support linkage to chromosome
4 or chromosome 12. Larger sample sets and denser and
more informative linkage analyses were pointing away
from the original chromosome 4 linkage observation, and
converging instead most strongly at 3q24-22.
Two linkage studies of successful aging in Amish
individuals over 80 years of age within a single 13-gen-
eration pedigree showed linkage to chromosomes 6, 7, and
14, different regions than those found in the longevity
linkage studies. Successful aging was defined as cogni-
tively intact and without depression, high functioning, and
satisfied with life. These studies (Edwards et al. 2011;
Edwards 2012) analyzed 263 cognitively intact Amish over
80 years old (74 successfully aged and 189 normally aged)
within 12 sub-pedigrees using 630,309 autosomal SNPs.
Linkage was found at 6q25-27, as well as association of a
SNP, rs205990, in the interval linked to the ‘successfully
aged’ phenotype. The chromosome 6 linkage identified in
the Amish is different from those identified in the Utah and
New England studies; this may reflect the different phe-
notype, or may be due to genetic factors specific to the
Amish founder population.
The largest linkage study to date was done in the multi-
site European Genetics of Healthy Aging (GEHA) Study,
which looked at 2118 European full sib-pairs over 90 years
old (Beekman et al. 2013). GEHA found linkage at 4
regions: 14q11.2, 17q12-q22, 19p13.3-p13.11, and
19q13.11-q13.32. The chromosome 14 linkage is at a dif-
ferent site from that observed in the Amish study; the large
chromosome 17 region overlaps the 17q21 locus observed
by Kerber et al. Fine mapping of these linkage regions
using GWAS data in a subset of 1228 unrelated nonage-
narians and 1907 controls identified a SNP near APOE at
the 19q locus as significantly associated with longevity.
Apolipoprotein E (apoE) isoforms are known risk factors
for cardiovascular disease (CVD) and Alzheimer disease
(AD), likely due to their involvement in inflammation,
elevated lipid levels, and oxidative stress (Huebbe et al.
2011). ApoE has three main isoforms: apoE2, apoE3 and
apoE4. Combined modeling in the GEHA study showed
that APOE4 (p = 0.02) and APOE2 (p = 1.0 9 10-5)
account for the linkage at 19q. The APOE linkage was
characterized by absence of APOE4, but enrichment for
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APOE2 among the nonagenarians. In this study the APOE2
allele is the stronger association, and the authors refer to
APOE as a longevity gene.
The multiple linkage signals observed in these studies
likely indicate genetic heterogeneity of longevity and
healthy aging in human populations. Interestingly, the
GEHA study observed heterogeneity among its multiple
geographic regions; Northern European subjects contribute
most to some of the linkage peaks they observe, including
the APOE locus. Gender-specific effects were also
observed, with a male-specific linkage peak at 8p and
female-specific ones at 15q and the 19q APOE locus
(Beekman et al. 2013). While the lack of association at the
other linkage regions in the GEHA study may be due to
power limitations, it could also imply that multiple rare or
‘private’ variants contribute to linkage but not association
at these loci.
Candidate gene association studies
Candidate genes examined for association with longevity
or healthy aging or related phenotypes fall into several
categories. They include genes nominated based on
observations of lifespan extension in model organisms; and
genes involved in lipid metabolism, immune response and
inflammation, stress response, and others. Candidate genes
tested for association with longevity and related pheno-
types have been the subject of several excellent reviews
(Christensen et al. 2006; Wheeler and Kim 2011; Ferrario
et al. 2012; Newman and Murabito 2013); an exhaustive
listing is beyond the scope of this review.
Of the candidate genes assessed for association with
longevity, variants in APOE and FOXO3A have been most
consistently replicated, though some candidate genes have
been associated with longevity phenotypes in more than
one population but not in all populations tested; many more
have been associated in a single study but failed to repli-
cate in others (reviewed by (Christensen et al. 2006)). In a
study of 1,344 healthy Italians aged 22–90, APOE4 was
found at lower frequency and APOE2 at higher frequency
in elderly and centenarians than in younger individuals
(e.g., Seripa et al. 2006); APOE2 is a putative protective
factor in this context and APOE4 can be considered a
‘frailty’ allele (Gerdes et al. 2000). FOXO3A is a homo-
logue of the C. elegans Daf-16 gene that is important in
control of lifespan in the worm (Hsin and Kenyon 1999); it
is part of the insulin/IGF1 signaling pathway. FOXO3A
variants have been associated with longevity in many
populations (reviewed in Wheeler and Kim 2011).
Additional genes show promise of great relevance to
healthy aging. A variant at CETP, for example, though
inconsistently associated with longevity in different popu-
lations (reviewed by (Christensen et al. 2006)), in 213
Ashkenazi Jewish individuals of average age 98 is asso-
ciated not only with longevity but also with additional
aging-related phenotypes including a desirable lipid profile
(Barzilai et al. 2003) and preservation of cognitive function
(Barzilai et al. 2006). Other recent studies with extensive
replication data are also encouraging. Association of a SNP
in a heat shock factor gene, HSF2 with all-cause mortality
was seen in the longitudinal Rotterdam Study (5,974 par-
ticipants and 3,174 deaths), with replication in eight pop-
ulation-based cohorts (Broer 2012).
Other candidate genes have been associated with lon-
gevity or healthy aging phenotypes in some but not all
studies. MTP, identified as a regional candidate at the 4q25
locus, failed to show replication of association with lon-
gevity in larger studies of approximately 1500 LLI each
(Beekman et al. 2006; Bathum et al. 2005; Nebel et al.
2005). Progeria genes have shown association with lon-
gevity in some studies. A haplotype of SNPs at LMNA, the
gene that is mutated in Hutchinson-Gilford progeria, was
associated with long life (age [95 years) in 873 LLI and
443 controls, and remained significant upon meta-analysis
of 3,619 subjects from four independent samples (Conne-
ely et al. 2012). Polymorphisms at WRN have shown
inconsistent associations with age (Castro et al. 2000;
Kuningas et al. 2006). Sirtuins mediate the effects of
caloric restriction, a non-genetic factor known to increase
life span in many organisms. The effect of polymorphisms
in sirtuin genes (SIRT1-7) on longevity and age-related
diseases was reviewed by Polito et al. (2010). There is
evidence that variants in SIRT3 (Rose et al. 2003) are
associated with longevity. A functional promoter variant at
DNA repair gene EXO1 was associated with longevity in
female centenarians (Nebel et al. 2009), but tagSNPs in the
gene showed no association with longevity in men (Morris
2013).
Given the multifactorial nature and likely genetic het-
erogeneity of healthy aging and longevity, as well as
environmental influences on these complex traits, it may
not be reasonable to expect that replication of candidate
gene studies would be uniform between populations. Rea-
sons for lack of replication include limitations of sample
size, rarity (low minor allele frequency) of actual variants,
and small true effect sizes. Poorly designed or under-
powered studies will result in false positives that legiti-
mately fail to replicate. For studies of longevity and heal-
thy aging, in particular, differences in phenotype or type of
study will also result in findings that are non-uniform
between studies. While larger case/control studies are fre-
quently suggested as a solution to the limitations of pres-
ent-day association studies, combining data from
populations with different lifestyles and genetic back-
grounds, even if well-matched for ethnicity, may obscure
true association signals.
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Genome-wide association studies
To date, SNPs in or near APOE are the only ones to
achieve genome-wide significance (GWS, generally
p B 5 9 10-8) in genome-wide association studies
(GWAS) of lifespan-related traits. In three GWAS of long-
lived individuals vs. younger controls, APOE was signifi-
cantly associated with longevity at the genome-wide level.
The first of these included 763 long lived (94–110 years)
and 1,085 control (45–77 years) from German biobanks
and replication in an independent set of German samples
(754 cases aged 95–108, 860 controls aged 60–75) (Nebel
et al. 2011). Only rs4420638 near APOC1 and in linkage
disequilibrium (LD) with APOE achieved GWS. GWAS of
403 unrelated nonagenarians (average age 94) from lon-
gevity families in the LLS vs. 1,670 controls (average age
58) showed similar results (Deelen et al. 2011a). Only one
of 62 SNPs carried forward to meta-analysis with 4,149
nonagenarian cases and 7,582 younger controls from the
Rotterdam study, the Leiden 85? study and the Danish
1905 Cohort reached GWS, rs2075650 at TOMM40 near
APOE. Meta-analysis of the APOE2 and APOE4 SNPs
showed significant associations of both SNPs with lon-
gevity, with E2 being protective of long life (OR 1.31, CI
1.17–1.46, p = 1.35 9 10-6), and E4 being deleterious
(OR 0.62, CI 0.56–0.68, p = 1.33 9 10-23). A third lon-
gevity GWAS (Sebastiani et al. 2012) included three
phases: a discovery phase with 801 New England cente-
narians (aged 95–119, many with a family history of
extreme longevity) vs. 914 controls genetically matched by
means of principal components analysis; a first replication
in 253 centenarians (89–114) vs. 341 genetically matched
controls; and a second replication with 60 additional cen-
tenarians (100–114) and unmatched controls. Of 243,980
SNPs analyzed only one, TOMM40 SNP rs2075650 near
APOE, reached GWS. Inverse association of APOE4 with
longevity (p = 5.3 9 10-3) was also detectable in the
Southern Italian centenarians study (SICS) of 440 LLIs
aged 90–109 and 553 young controls aged 18–45 (Malovini
et al. 2011), despite the known lower frequency of the E4
allele in Southern, as compared with Northern, Europe
(Haddy 2002).
Other GWAS of lifespan-related phenotypes revealed
no associations that were significant at the genome-wide
level. A GWAS of the Framingham health study (Lun-
etta et al. 2007) (258 Original Cohort and 1,087 Off-
spring individuals, members of the 330 largest families
in the study) revealed no GWS SNPs for any of five
aging-related phenotypes. Newman et al. (Newman et al.
2010) meta-analyzed four cohort studies in the cohorts
for heart and aging research in genomic epidemiology
(CHARGE) Consortium for survival to at least 90 years
of age. Cases were 1,836 people who achieved survival
to at least 90; controls were 1,955 participants who died
aged 55–80. SNPs were genotyped and imputed in sub-
jects of European ancestry, with systematic elimination
of outliers and correction for population stratification.
Replication was carried out in the LLS (950 long-lived
probands and 744 partners of their offspring and 680
blood bank donors) and the Danish 1905 Cohort Survey
(2,262 long-lived participants and 2007 Danish twin
study controls aged 46–68). No SNPs reached genome-
wide significance.
Walter et al. (2011) conducted a meta-analysis of
GWAS of nine longitudinal cohort studies in the CHARGE
Consortium, including 25,000 unselected people of Euro-
pean ancestry. They analyzed two continuous traits, all-
cause mortality, and event-free survival (where ‘event’ was
defined as myocardial infarction, heart failure, stroke,
dementia, hip fracture, or cancer). No SNPs reached GWS
for either phenotype. SNPs near APOE reached only
nominal significance in the CHARGE study (Walter et al.
2011), in contrast to the results of GWAS of centenarians,
in which APOE has been a significant and replicable
finding. The CHARGE meta-analysis contained few
extremely old individuals, and so in comparison with
centenarian studies or those targeting long-lived healthy
individuals, has examined earlier mortality and events, a
different phenotype. The Framingham Study GWAS
(Lunetta et al. 2007), which also showed no GWS SNPs
also represents a much younger group, on average, than
studies of oldest old or centenarians. This may mean that
different genes and variants may come into play in dif-
ferent phases of aging, with APOE being most relevant at
older ages. Earlier mortality is often related to lifestyle as
well, and the heritability of aging is lower at younger ages,
as described above.
A genome-wide association study of copy number
variants (CNVs) in the Rotterdam study RS1 cohort, with
replication in the RS2 cohort and the FHS, found that large
common deletions are associated with mortality (vs. sur-
vival) at old age (Kuningas et al. 2011a). They tested 312
common CNV regions and measures of CNV burden for
association with mortality during follow-up. A higher
burden of CNVs of 500 kb or more in size was associated
with mortality. Two specific regions were also associated
with mortality, 11p15.5 and 14q21.3. The 11p15.5 associ-
ation, which would survive Bonferroni correction for 312
tests, includes insertions and deletions which were ana-
lyzed together relative to non-carriers; it contains 41 genes
including some related to longevity or complex diseases.
The 14q21.3 region contains no genes and is characterized
only by deletions. Runs of homozygosity, which can
indicate presence of recessive loci, were not associated
with survival to old age in this cohort (Kuningas et al.
2011b).
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Analyses of phenotypes that may influence long-term
good health have also been undertaken. Personality traits
are associated with healthy aging and longevity (Terrac-
ciano et al. 2008). In the LLFS, a GWAS of five personality
factors in 583 families with 4,595 individuals and repli-
cation in 1,279 other subjects identified a locus associated
with agreeableness, and identified several significant
age 9 SNP interactions that may affect longevity through
effects on personality (Bae et al. 2013).
In contrast to the results of longevity GWAS, GWAS of
common complex diseases have revealed hundreds of
SNPs associated with cancers, CVD, diabetes and other
age-related diseases, albeit with increasing numbers of
associations found with increasing GWAS size. One
explanation for this may be that the phenotypes of healthy
aging and longevity may be much more complex than those
of these complex diseases, in part because they often
(depending on phenotype definition) involve absence of
specific complex diseases. If GWAS studies of survival to
elderly ages are even more confounded by environmental
(E) factors than GWAS of diseases, combining studies
from different populations in pooled or meta-analyses may
complicate the E effects even more. In studies of older
individuals, it is particularly hard to control for E factors
experienced over many decades of life.
Effects of variants that do not achieve p B 5 9 10-8
SNPs at only one locus, APOE, have achieved Bonferroni-
corrected levels of GWS in GWAS of longevity. By current
standards these GWAS, which involved fewer than 1,000
centenarians, or a few 1,000 nonagenarians, are modest in
size. Larger GWAS may in theory allow additional SNPs to
achieve this threshold. There are other indications, how-
ever, that support the idea that SNPs that do not reach this
threshold of GWS may be biologically important, either
individually or through their joint effects. Several studies
used a variety of techniques to analyze collections of
nominally longevity-associated SNPs to determine if they
act in concert to affect lifespan.
In the Framingham study GWAS of 5 aging-related
phenotypes (Lunetta et al. 2007) observed that SNPs in
some candidate genes, including SNPs near the Werner
syndrome gene WRN and FOXO1A, as well as GAPDH,
KL, LEPR, PON1, PSEN1, and SOD2 were associated with
age at death. Kulminski and Culminskaya (2011) used
Framingham Affymetrix 50 K SNP data to perform GWAS
of four endophenotypes (CVD, cancer, systolic blood
pressure, and total cholesterol) to identify 63 SNPs that
were associated at p \ 10-6 with at least one endopheno-
type. 76 genes at or near these SNPs were enriched in terms
of Gene Ontology annotations related to aging-relevant
processes. Yashin et al. (2010) hypothesized that lifespan
depends on the number of small-effect longevity alleles
present in individual genomes. They re-analyzed Fra-
mingham 550 K SNP data and identified 169 SNPs asso-
ciated at p \ 10-6. The number of these SNPs carried by
an individual correlated with lifespan and explained 21 %
of its variance; in contrast, randomly chosen SNPs did not
correlate with lifespan.
Gene set analysis of GWAS data from the LLS and
Rotterdam studies was used to show that genes in the
insulin/IGF-1 signaling (IIS) and telomere maintenance
TM pathways are associated with longevity (Deelen
2011b). 1021 and 88 GWAS SNPs were identified within
10 kb of 68 IIS and 13 TM genes, respectively. Both
pathways were associated with longevity. Nine IIS genes
(AKT1, AKT3, FOXO4, IGF2, INS, PIK3CA, SGK, SGK2,
and YWHAG) and one TM gene (POT1) were the main
determinants of the association.
Sebastiani et al. (2012) constructed a model in which
281 SNPs showed 89 % sensitivity and 89 % specificity to
predict longevity in their GWAS Discovery set, and
58–61 % specificity and 58–85 % sensitivity in indepen-
dent sets. They call this a ‘genetic signature of exceptional
longevity’. These SNPs explain nearly 20 % of the heri-
tability of extreme longevity. They find that the TOMM40
SNP near APOE alone has poor predictive value; removing
it from the model reduces specificity and sensitivity by
only 1 %. The 281 SNPs include 137 in 130 genes,
including LMNA, WRN, SOD2, CDKN2A, SORCS1 and
SORCS2, and GIP. This set of 130 genes is highly and
significantly enriched for those related to Alzheimer dis-
ease (38 genes), 42 related to dementia, 38 to tauopathies,
24 to CAD, and several to neoplasms.
GWAS of the SICS Study of 410 LLI and 553 younger
controls identified 67 SNPs that reached a permutation-
defined level of genome-wide significance of p \ 10-4
(Malovini et al. 2011). Among them was rs10491334 at the
calcium/calmodulin-dependent protein kinase IV (CAM-
KIV) that replicated in 116 additional LLI and 160 con-
trols. Malovini et al. demonstrate that CAMK4
phosphorylates and activates survival proteins FOXO3A,
AKT, and SIRT1. Homozygous carriers of the minor allele
had lower CAMKIV protein expression and were under-
represented among LLI’s, consistent with a deleterious
effect of this allele on longevity.
The biological relevance of other SNPs besides those at
APOE is also strongly supported by similarities between
the results of human GWAS and mouse lifespan studies.
Eight of the ten top CHARGE SNPs detected by GWAS,
but which did not achieve GWS, correspond to mouse
lifespan quantitative trait loci (QTL) (Murabito et al.
2012). These studies connect GWAS findings that do not
reach GWS with many genes that are relevant to aging or
age-related diseases. In several cases, this convergence
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with genes of biological interest is statistically unlikely to
be due to chance and is likely to reflect the presence of true
association signals that are not consistent enough to be
replicated predictably as candidate genes or achieve GWS,
or have effects that are too subtle to be detected individ-
ually. Such potential true signals may be more affected by
‘E’ factors than those that have been replicated, i.e., APOE
and FOXO3A. As pointed out by Yashin et al., the same
sets of variants would not be expected to work in all
populations because of differences in environment (Yashin
et al. 2010).
The extremely long-lived do not lack risk alleles
for common complex diseases
Several recent studies have shown that centenarians do not
carry smaller numbers of risk alleles for common complex
diseases than average people. In an important paper in
2010, Beekman et al. (2010) studied two case/control
collections: (1) 723 nonagenarian siblings (mean age 94)
from the LLS vs. 721 unrelated younger controls (mean age
52), and (2) 979 long-lived individuals over 85 (mean age
87) from the pop-based Leiden 85? study vs. 1,167
younger controls (mean age 41) from the Netherlands Twin
Register. They looked at 30 SNPs known to be associated
with CVD, cancer or type 2 diabetes (T2D). The cases and
controls each carried an average of 27 disease risk alleles.
The distribution of risk alleles was the same in elderly and
young subjects. Beekman et al. note that ‘‘GWAS-identi-
fied disease risk alleles do not compromise human lon-
gevity’’ and suggest that a lack of rare disease factors, or
the presence of protective factors, is at work in the long-
lived individuals. It is important to note, however, that
CVD, cancer, and T2D are diseases that have very clear
lifestyle components and that part of the effect could be
due to lifestyle differences.
Mooijaart et al. (2011) extended this observation the
following year, showing that ‘‘SNPs associated with T2D
and identified by GWAS are not major determinants of the
beneficial glucose tolerance that characterizes familial
longevity.’’ They compared the offspring of the LLS long-
lived individuals with the offspring’s spouses and other
controls. The LLS offspring had a better metabolic profile
and better glucose tolerance than same-age controls,
although the frequency of 15 known T2D SNPs did not
differ between the two groups. When individuals were
compared within each group, however, glucose levels did
correlate with the number of T2D SNPs. They speculate
that the LLS offspring may have protective factors that
improve their metabolic profile and glucose tolerance in
spite of the presence of T2D GWAS SNPs. This compar-
ison, using same-age groups of individuals, clearly points
to protective genetic factors contributing to preservation of
a healthy phenotype, rather than lifestyle and environ-
mental factors that should be very similar (at least in
adulthood) between the offspring and their spouses.
Sebastiani et al. (2012) also noted that there was not a
substantial difference in the numbers of 1,214 known dis-
ease-associated SNPs in centenarians and controls. A
similar observation was made in their whole genome
sequence data from one male and one female supercente-
narian (Sebastiani et al. 2011).
These important and perhaps surprising results show
that extreme longevity, and the long-term good health that
often accompanies it, is not incompatible with the presence
of many disease risk alleles. At least for the common SNPs
associated with common complex diseases, it is not the
absence of ‘bad’ alleles, but more likely the presence of
‘good’ alleles that influences longevity, though effects of
‘good’ environmental factors may also contribute. Protec-
tive factors of some kind may allow these risk variants to
not be manifest. These results also have implications
beyond the study of longevity—in an age when substantial
effort is being invested in personalized disease risk pre-
diction, the presence of many disease alleles that are non-
penetrant in some individuals potentially complicates pre-
dictions of disease.
Do ‘good’ variants protect against ‘bad’ ones?
One mechanism for a lack of effect by an undesirable allele
is the ‘buffering’ mechanism explored by Barzilai et al.
They propose that some individuals who show exceptional
longevity may do so despite the presence of unfavorable
alleles because those alleles are buffered by favorable
alleles in other genes (Bergman et al. 2007). They suggest
that buffering gene variants (longevity variants) will show
a monotonic increase in frequency from early old age (65)
to later ages; examples of buffering genotypes are CETP
VV, APOC3 CC, and a ?2019 deletion in ADIPOQ.
Buffered alleles, in contrast, should show a U-shaped fre-
quency curve, higher at younger ages, dipping low in early
old age, and then increasing in the exceptionally old (who
have the ‘buffering’ protective genotype that allows dis-
ease-related variants to accumulate); examples of buffered
genotypes are heterozygotes for deleterious alleles of
KLOTHO and LPA. Importantly, Bergman et al. use a
cross-sectional study design, with 1,200 subjects in their
6–11th decades of life to show experimental support for the
buffering hypothesis; their data support the idea that CETP
VV genotype buffers the deleterious effects of an LPA
genotype. They show a genetic interaction between CETP
genotype and LPA; LPA heterozygotes with the CETP IV/
II genotypes monotonically decrease in frequency with age,
but those in CETP VV individuals increase from age 70
onward. They argue that case/control analyses are
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insufficient to reveal this effect because it does not reveal
the shape of the allele frequency 9 age curve.
Earlier observations are also explained by a buffering
mechanism. De Benedictis et al. (1998) described an age-
related convex trajectory of a 30APOB-VNTR genotype
that they interpret as consistent with crossing mortality
curves relevant to subgroups of individuals with different
genotypes. A X-sectional study of 800 healthy aging sub-
jects from 18 to 109 years free of clinically apparent dis-
ease genotyped variants in APOA1, APOC3, and APOA4
(Garasto et al. 2003). They noted that an allele of APOA1
that correlated with higher serum LDL-C was paradoxi-
cally increased in frequency in the oldest old. The authors
called it ‘‘another genetic paradox of centenarians.’’ While
this observation could reflect population stratification in the
different age groups, it may also be due to the U-shaped
curve of a buffered gene.
The buffering mechanism may also explain some of the
inconsistency in the findings for MTP. Huffman et al.
(2012) find that MTP CC is a deleterious genotype that is
buffered by any of three longevity genotypes of CETP,
APOC3, or ADIPOQ. MTP CC shows a U-shaped curve,
declining ages 55–85, and then dramatically increasing in
those who live 90 or more years. If this MTP genotype is
observed at high frequency in centenarians, but only in the
presence of specific protective variants, this may in part
explain why the linkage at chromosome 4 was not observed
consistently between studies.
Buffering has been described in model organisms. The
heat-shock protein Hsp90 is known to buffer genetic var-
iation in Drosophila, allowing it to accumulate under
neutral conditions (Rutherford and Lindquist 1998). Such a
gene is known as a phenotypic capacitor, and it masks the
presence of phenotypic variation. It is interesting to spec-
ulate that protective genetic variants carried by centenari-
ans may be capacitors for the disease risk variants we now
know they carry at, on average, the same frequency as
other people. Identification of buffering/capacitor genes
and study of their function will be necessary to understand
the longevity phenotype. It will also be important to
determine if such capacitors operate in healthy aging as
well as extreme longevity. Because such variants are likely
rare, intensive study of rare individuals at the upper ends of
the human lifespan and healthspan, perhaps by whole
genome sequencing and examination of unusual variants
they carry, is paramount.
The interaction between buffering and buffered genes
and genotypes also has implications for study design. The
exquisite studies carried out by Barzilai’s group are done in
a single well-defined ethnicity, Ashkenazi Jewish individ-
uals. Since a buffered gene will only show a distinctive
U-shaped curve in the presence of its buffer, and a buffer
may only be advantageous in the presence of a deleterious
gene that it buffers, this underscores the importance of
avoiding population stratification in such studies. If some
of the associations detected to date in case/control studies
of healthy aging and longevity are actually underlain by
genotypes with U-shaped curves, the choice of ages for the
cases and controls will greatly affect whether an associa-
tion is detected, and may explain some failures of associ-
ations to replicate. Finally, the concept of buffering genes
has implications for the use of centenarians, or excep-
tionally healthy elderly individuals as super-controls for
disease studies; if the exceptional elderly are healthy
because of a protective factor rather than lack of a disease
allele, their use as an extreme comparison group may not
necessarily be helpful.
Do differences in lifestyle affect these studies?
Given that lifestyle is expected to have a greater impact
than genetics on healthy aging, it seems unlikely that dif-
ferences in lifestyle are not confounding association studies
of longevity and healthy aging. It is challenging to quantify
lifestyle in an optimal comparison group for, for example,
centenarians. Younger control groups inevitably have dif-
ferent lifestyles than the elderly had at their age. For
example, the CHARGE consortium (Newman et al. 2010),
which compared individuals who survived to at least 90 to
those who died aged 55–80, found that the younger con-
trols had higher rates of smoking.
The Longevity Gene Study overcame the birth cohort
limitation using pre-existing lifestyle data from 3,164
NHANES controls of the same birth cohort as 477 Ash-
kenazi Jewish individuals aged 96–109 (Rajpathak et al.
2011). They found no obvious differences in lifestyle and
suggested that the long-lived individuals may interact with
lifestyle factors differently than others. This study, how-
ever, did note subtle differences between the long-lived and
comparison groups. They saw significantly fewer obese
men, more overweight women, and fewer obese women in
the long-lived group; in addition, more control men
smoked. These differences, combined with recall limita-
tions of the long-lived group, imply that this analysis may
have missed many small lifestyle differences that could add
up to substantial health differences. It will likely be diffi-
cult to take into account all but the largest lifestyle factors
when planning GxE studies of longevity and healthy aging.
Biomarkers of exposures may vary not only with exposure
but also over time, complicating the use of such methods
for these phenotypes.
Association studies of mitochondrial variants
Mitochondria are thought to be important to aging due
to their key roles in oxidative phosphorylation, cell
Hum Genet (2013) 132:1323–1338 1331
123
metabolism, and apoptosis. A relationship of variation in
the mitochondrial genome with health and/or longevity is
implied by the observation that age at death correlates
more closely with the age at death of a person’s mother
more so than that of the father (Brand et al. 1992). Asso-
ciations of mitochondrial genome sequence variants or
haplogroups (combinations of specific variants that corre-
late with specific populations) with healthy aging or lon-
gevity have been noted in many populations including, for
example, Italian (De Benedictis et al. 1999), Japanese
(Tanaka et al. 1998), Amish (Courtenay et al. 2012), Chi-
nese Uygur (Ren et al. 2008), Costa Rican (Castri et al.
2009), Ashkenazi Jewish (Iwata et al. 2007), Irish (Ross
et al. 2001), and Finnish individuals (Niemi et al. 2003).
The associations observed are inconsistent between popu-
lations and do not involve the same variant or haplogroup.
This lack of consistency may be due in part to the relatively
small size of many of these studies. Three common prob-
lems have been noted about such studies: inadequate
matching of cases and controls, inadequate correction for
multiple tests, and undetected population stratification
(Shlush et al. 2008).
Interestingly, when the frequencies of different mito-
chondrial haplogroups are plotted for Italian individuals
aged 20 to over 100, the curve shapes observed include
monotonic increase for haplogroup J, and a U-shaped curve
for haplotype H (de Benedictis et al. 2000), reminiscent of
the ‘longevity’ and ‘buffered’ variants described earlier. A
variant at the origin of replication of the mitochondrial
heavy strand, C150T, has been observed at higher fre-
quencies in centenarians, both through inheritance and
through somatic increase in frequency, with some indi-
viduals achieving homoplasmy for this variant in their
lymphocytes and monocytes, but not in granulocytes; a
selective advantage of achieving high frequency of this
variant in at least some cell types has been suggested
(Zhang et al. 2003). Interactions between nuclear genome
variants and both inherited and somatic mitochondrial
variants have also been suggested to play a role in aging
and longevity (Santoro et al. 2006; Tranah 2011).
Genome sequencing
Sebastiani et al. (2011) recently reported the whole genome
sequencing of one male and one female supercentenarian
of European ancestry from the NECS. The genomes of
these exceptionally long-lived individuals were similar, in
terms of the rate of nonsynonymous SNPs and number of
indels, to other genomes sequenced to date. They have a
similar number of known disease-associated variants to
other genomes showing that their exceptional lifespan does
not seem to be due to lack of known disease-associated
variants. It is possible, though, that they failed to inherit a
combination of variants that would have acted together to
cause disease. Both supercentenarians lacked APOE4
alleles. They do not carry most of the longevity variants
reported previously in the literature, implying that these
known variants are not necessary for longevity. It is pos-
sible that they carry as yet undiscovered protective vari-
ants. One per cent of the variants observed were novel.
Interestingly, an excess of coding region variants was seen
in genes closest to GWAS-identified longevity variants, an
observation that supports the idea that rare variants of these
genes may contribute to the longevity phenotype.
Telomeres in healthy aging and longevity
Telomeres are indisputably important to aging. Telomeres
shorten with age and are considered to be a biomarker of
age. The role of telomere biology in healthy aging and
disease was recently reviewed (Zhu et al. 2011). Leukocyte
telomere length (LTL) has been correlated with measures
of health and ability in elderly individuals. In a commu-
nity-based cohort of 70- to 79-year-olds, LTL was associ-
ated with more years of healthy life; LTL was suggested to
be a biomarker of healthy aging (Njajou et al. 2009).
Louisiana Healthy Aging Study results concurred with this
observation; LTL was correlated with measures of healthy
aging in an age-dependent way (Kim et al. 2012). LTL was
also found to correlate positively with physical ability (but
not cognitive function) in Danish twins aged at least
77 years (Bendix et al. 2011) and inversely with disability
in American seniors (Risques et al. 2010). Ashkenazi
centenarians and their offspring also showed longer telo-
meres, for their age, than controls; longer telomeres cor-
related with less disease (Atzmon et al. 2010). In contrast,
in a study of Canadian ‘Super-Seniors’ (individuals aged at
least 85 and never diagnosed with cancer, cardiovascular
disease, Alzheimer disease, major pulmonary disease or
diabetes) the healthy oldest-old did not have exceptional
telomere length for their age, but showed less variability in
telomere length than mid-life controls, implying that they
may be selected for optimal rather than extreme telomere
length (Halaschek-Wiener et al. 2008).
Variation in genes involved in telomere maintenance has
also been associated with longevity. One SNP at SIRT1
(Kim et al. 2012) and one in TERC (Soerensen et al. 2012)
are associated with both LTL and longevity. Detailed
analysis of TERT and TERC in Ashkenazi centenarians
showed an excess of genetic variation in both genes in the
centenarians and identified a TERT haplotype associated
with extreme longevity (Atzmon et al. 2010). Gene set
analysis of GWAS data also supported the relevance of
telomere maintenance (Deelen et al. 2013). Overall, the
relationship between telomeres, aging, healthy aging, and
longevity is multi-layered. Telomere maintenance is an
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important process in aging, and also a biomarker of it. LTL
is a biomarker of aging and of healthy aging. Variation in
telomere maintenance genes appears to affect both telo-
mere length, and life span and health span in humans.
Somatic genetics of aging
Two recent large-scale analyses of data from GWAS
studies have established that mosaicism for large genomic
alterations increases with age (Laurie et al. 2012; Jacobs
et al. 2012). In one study, data for 50,222 subjects found
that \0.5 % of people aged \50, and 2–3 % of elderly
(2.7 % in subjects [80 years), have detectable mosaicism
in peripheral blood. Age was a significant predictor of
mosaic status, but sex, ancestry, and smoking status were
not. The second study used data from 31,717 cancer cases
and 26,136 controls from 13 GWAS studies and found
detectable clonal mosaicism in 0.87 % of individuals. In
the cancer-free controls, they found mosaicism in 0.23 %
of those\50 years old and in 1.91 % of those aged 75–79,
a significant difference (p = 4.8 9 10-8). Somatic mosa-
icism (heteroplasmy) of the mitochondrial genome also
increases over the lifespan (Sondheimer et al. 2011). Of
course, telomere shortening is another somatic genomic
change that occurs over the human lifespan. Such somatic
changes are both a genetic aspect of aging and an aging-
related phenotype.
Epigenetics and longevity/aging
Epigenetics, at the interface between the genome and the
environment, is emerging as an important factor in lon-
gevity, and has been the subject of recent excellent reviews
(Gravina and Vijg 2010; Ben-Avraham et al. 2012).
Methylation patterns change with age, and discordance in
methylation between MZ twins also increases with age
(Talens et al. 2012), an observation consistent with the
effect of environment and lifestyle on the epigenome.
Studies of DNA methylation support the idea that aging is
associated with a relaxation of epigenetic control and that
this epigenetic drift may affect the development of aging-
related diseases (Gravina and Vijg 2010). An epigenome-
wide association scan (EWAS) identified age-related dif-
ferentially methylated regions as well as differentially
methylated regions associated with age-related phenotypes
(Bell et al. 2012). Whole genome bisulfite sequencing of
DNA from CD4? T cells of a centenarian and a newborn
identified differentially methylated regions that were usu-
ally hypomethylated and less correlated with methylation
of adjacent CpG dinucleotides in the centenarian (Heyn
et al. 2012). These results support the idea that small
cumulative DNA methylation changes accumulate over a
lifetime. Age-related temporal changes in DNA
methylation also show significant familial clustering,
indicating that methylation maintenance is a familial trait
(Bjornsson et al. 2008). A study of DNA methylation in
centenarians and their offspring compared with the off-
spring of non-long-lived individuals and young individuals
showed that the offspring of the centenarians delay age-
related methylation changes (Gentilini 2012). A landmark
paper by Hannum et al. (2013) offers an explanation for
this familiality. They used methylome analysis to compare
human aging rates in individuals of age 19–101 and iden-
tify methylation QTLs (meQTLs) (including one at methyl-
CpG binding domain protein 4) that affect it. Indeed, trans-
generational epigenetic inheritance of extended lifespan
has been demonstrated in C. elegans (Greer et al. 2011).
It is likely that the effects of epigenetic changes mani-
fest in part by effects on gene expression. Longevity-
selected lines of Drosophila show gene expression profiles
that are similar to younger control flies (Sarup et al. 2011).
This type of observation is more difficult to make in
humans, however. Several human studies have compared
gene expression between LLI and younger individuals.
Blood miRNA expression differences between LLI and
younger controls identified genes known to be differen-
tially expressed in age-related diseases (ElSharawy et al.
2012). This study design, however, does not allow dis-
crimination between genes that are differentially expressed
because they are involved in longevity, related to chrono-
logical age, or affected by environmental differences
between the old and young groups. A cross-sectional
analysis of individuals aged 50–90, and centenarians, was
used to identify a miRNA, miR-363*, whose expression
declined with age but was preserved at youthful levels in
the centenarians (Gombar et al. 2012). The Leiden Lon-
gevity Study, however, used LLI and their offspring to
show that RPTOR in the mTOR pathway is differentially
expressed between the offspring of the LLI and their
spouses (Passtoors et al. 2013). The study design issues that
are important to avoid confounding by lifestyle factors in
studies of inherited factors will be even more important in
gene expression studies. It seems likely that as yet
unidentified genetic factors and lifestyle practices that help
us maintain a favorable epigenetic profile and optimal gene
expression will be important in longevity and healthy
aging.
Conclusions
To date, studies of longevity and healthy aging have shown
few consistent and many inconsistent results. This is
probably due in part to the nature of the variants we seek to
find, which may be rare or even private, may act in concert
or as a ‘signature’, and which may buffer against the
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presence of other variants. It is also due to inter-ethnic
differences, population stratification, differences in phe-
notype definition and study design, effects of and con-
founding by known and unrecognized non-genetic factors
in part due to cohort effects, and exacerbation by insuffi-
cient sample size. Nevertheless, the results of longevity
studies to date establish their importance for our under-
standing of health and disease.
Only one gene has emerged as consistently found in
studies of LLI, APOE, though another, FOXO3A, was
replicated in multiple candidate gene studies. Additional
candidate genes are associated in more than one but not all
studies. Many of these correspond to signals that hover
below GWS in GWAS studies, and when analyzed together
for commonalities of pathways or other processes by means
such as gene set analysis, as a group are significantly
associated with these phenotypes. Epigenetics is quickly
emerging as a critical aspect of aging and longevity.
Centenarians delay age-related methylation changes, and
they can pass this methylation preservation ability on to
their offspring, probably via genetic variants that affect
methylation QTLs.
Importantly and perhaps surprisingly, centenarians
appear to have the same numbers of GWAS-identified
common disease variants as ordinary people, and yet they
have lived long and, to a great extent, free of disease.
Specific examples support the idea that centenarians may
have advantageous alleles of ‘buffering’ genes that allow
them to remain healthy despite the presence of ‘buffered’
deleterious alleles in other genes. It will be important to
determine how generalizeable this is—does it apply only to
a few genes, or is it a general mechanism for suppression of
disadvantageous alleles of many genes? As others have
pointed out (Bergman et al. 2007), a longevity gene that
buffered frailty alleles in several other genes would be a
desirable drug development tool. Understanding this will
affect not only personalized medicine but also our overall
interpretation of genomes, and could even give us the
information needed for rational design of agents to re-
create this desirable scenario in those not lucky enough to
inherit it.
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